Articles tagged "Bone marrow transplantation"

2017 American Transplant Congress
Two Months Delayed Induction of Mixed Chimerism After Heart and Kidney Cotransplantation in Nonhuman Primates.
K. Huh,¹ W. Sommer,¹ K. Robinson,¹ X. Wu,¹ J. Paster,¹ I. Hanekamp,¹ A. Dehnadi,¹ T. Kawai,^1,2 R. Smith,³ R. Colvin,^1,3 G. Benichou,¹ J. Madsen.^1,4
¹Center for Transplantation Sciences, Department of Surgery, Massachusetts General Hospital, Boston, MA; ²Department of Surgery, Massachusetts General Hospital, Boston, MA; ³Department of Pathology, Massachusetts General Hospital, Boston, MA; ⁴Division of Cardiac Surgery, Department of Surgery, Massachusetts General Hospital, Boston, MA
Background We have previously achieved transplant tolerance in cynomolgus recipients cotransplanted with heart and kidney by treating recipients with standard triple drug immunosuppression for 4…
2016 American Transplant Congress
Three-Year Outcome After HSCT with Subsequent KT from the Same Haploidentical Donor without Immunosuppression.
C. Schwarz,¹ A. Lawitschka,² G. Böhmig,³ E. Dauber,⁴ H. Greinix,⁵ N. Kozakowski,⁶ F. Mühlbacher,¹ G. Berlakovich,¹ T. Wekerle.⁷
¹Dept. of Surgery, Div. of Transplantation, Medeical University of Vienna, Vienna, Austria; ²St. Anna Children's Hospital, Vienna, Austria; ³Dept. of Internal Medicine, Division of Nephrology, Medical University of Vienna, Vienna, Austria; ⁴Dept. of Transfusion Medicine, Medical University of Vienna, Vienna, Austria; ⁵Dept of Internal Medicine, Div of Hematology, Medical University of Graz, Graz, Austria; ⁶Dept. of Clinical Pathology, Medical University of Vienna, Vienna, Austria; ⁷Section of Transplantation Immunology, Dept. of Surgery, Medical University of Vienna, Vienna, Austria.
Allogeneic hematopoietic stem cell transplantation (HSCT) can lead to donor-specific tolerance. Patients reported in the literature that underwent kidney transplantation (KT) after a previous HSCT…
2016 American Transplant Congress
Nontuberculous Mycobacterial Infection Among Allogeneic Hematopoietic Stem Cell Transplant Recipients: A 16-Year Cohort Study.
A. Alghamdi, J. Lipton, C. Rotstein, D. Kumar, A. Humar, T. Mazzulli, S. Husain.
University Health Network, Toronto, Canada.
Background: Nontuberculous mycobacteria (NTM) infections in hematopoietic stem cell transplant (HSCT) recipients can be associated with significant morbidity and mortality.Methods: We identified all allogeneic HSCT…
2016 American Transplant Congress
Hematopoietic Cell Transplant and Solid Organ Transplantation: A First Report of the U.S. Experience.
M. Gupta, M. Levine, P. Abt.
Surgery, Division of Transplant Surgery, University of Pennsylvania, Philadelphia, PA.
The prevalence of patients who receive both a hematopoetic cell(HCT) and solid organ transplantation(SOT) is rising. There have been no large scale studies of HCT…
2016 American Transplant Congress
HLA Identical or Haploidentical Combined Kidney and Bone Marrow Transplantation for Multiple Myeloma with End-Stage Renal Failure.
T. Kawai,¹ Y.-B. Chen,¹ M. Sykes,² C. Benedict,¹ N. Tolkoff-Rubin,¹ B. Day,¹ S. McAfee,¹ K. Ballen, S. David,¹ T. Spitzer.¹
¹Massachusetts General Hospital, Boston; ²Columbia University, New York.
Patients with multiple myeloma (MM) who developed end-stage renal disease (ESRD) are generally not eligible for either kidney transplantation or allogeneic stem-cell transplant. We performed…
2016 American Transplant Congress
Tolerance Induction with Donor Bone Marrow Transplantation in Kidney Transplantation.
H. Park,¹ N. Lee,¹ S. Lee,¹ G. Choi,¹ C. Kwon,¹ S. Kim,¹ J.-W. Joh,¹ M. Kim,² Y. Kwon,² S.-K. Lee.¹
¹Department of Surgery, Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, Republic of Korea; ²Transplantation Research Center, Samsung Biomedical Research Institute, Seoul, Republic of Korea.
Tolerance induction is considered to be a final goal in the field of organ transplantation. We have performed simultaneous bone marrow and kidney transplantation in…
2016 American Transplant Congress
Direct IL-33 Stimulation of T Regulatory Cells via Suppression of Tumorigenicity 2 (ST2) Is Required for Effective Control of Alloimmune Responses.
X. Zhang,^1,3 B. Matta,¹ D. Reichenbach,² B. Blazar,² H. Turnquist.¹
¹Dept of Surgery, Starzl Transplantation Inst, Pittsburgh, PA; ²Dept of Pediatrics, Univ of Minnesota, Minneapolis, MN; ³Xiangya School of Medicine, Central South University, Changsha, Hunan, China.
Background: IL-33 is a pleotropic cytokine that can protect against cardiac transplant rejection by expanding regulatory T cells (Treg), particularly a Treg subset expressing the…
2016 American Transplant Congress
Long-Lasting Skin Allograft Tolerance Induced and Maintained by Short-Term Vascularized Bone Marrow Transplant in a Mouse Model.
C.-H. Lin,¹ M. Anggelia,¹ H.-Y. Cheng,¹ Y.-L. Wang,¹ W.-Y. Chuang,¹ C.-H. Lin,¹ G. Brandacher.²
¹Center for Vascularized Composite Allotransplantation, Department of Plastic and Reconstructive Surgery, Chang Gung Memorial Hospital, Taoyuan, Taiwan; ²Department of Plastic and Reconstructive Surgery, Vascularized Composite Allotransplantation (VCA) Laboratory, Johns Hopkins University School of Medicine, Baltimore, MD.
Background: Accumulating evidences indicate that vascularized bone marrow transplantation (VBMT) plays a critical role in inducing tolerance of vascularized composite allografts (VCA). Recipients with long-term…
2016 American Transplant Congress
Post Transplantation High-Dose Cyclophosphamide Treatment Promotes Immune Tolerance After Skin, Solid Organ, and Vascularized Composite Allotransplantation.
G. Furtmüller,¹ B. Oh,¹ M. Fryer,^1,4 P. Akre,¹ S. Ganguly,² J. Dodd-o,³ D. Cooney,¹ G. Raimondi,¹ W. Lee,¹ L. Luznik,² G. Brandacher.¹
¹Department of Plastic and Reconstructive Surgery, Johns Hopkins Medicine, Baltimore, MD; ²Immunology - Sydney Kimmel Cancer Center, Johns Hopkins Medicine, Baltimore, MD; ³Department of Anesthesiology, Johns Hopkins Medicine, Baltimore, MD; ⁴Department of Microbiology and Immunobiology, Harvard Medical School, Boston, MA.
Background: Developing novel approaches to minimize/avoid immunosuppression by induction of immune tolerance represents the prime task in the field of transplantation. Methods: Murine skin, heart,…
2016 American Transplant Congress
Administration of IL-33 Before Allogeneic Stem Cell Transplantation Expands Recipient Treg That Prevent Graft- vs. Host Disease.
B. Matta,¹ D. Reichenbach,² X. Zhang,¹ B. Koehn,² L. Mathews,¹ C. Feser,² M. Smith,² Q. Liu,¹ R. Zeiser,³ B. Blazar,² H. Turnquist.¹
¹Dept of Surgery and Starzl Transplant Inst, Univ of Pittsburgh Sch of Med, Pittsburgh, PA; ²Dept of Pediatrics, Univ of Minnesota, Minneapolis, MN; ³Univ Med Cntr Freiburg, Freiburgh, Germany.
Background: During allogeneic hematopoietic cell transplantation (alloHCT), non-hematopoietic cell IL-33 is augmented and released by recipient conditioning to promote Type 1 alloimmunity and lethal acute…